Browse medicines
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Showing 1–7 of 7 records
Cardarine (GW501516; also written GW1516 in anti-doping documents)
Small chemical medicineIn Phase 2 testingDetailed recordUse listed on the medicine record
Abandoned cholesterol and metabolic drug, still sold as a fat burner
Ipamorelin (Also written NNC 26-0161. No trade name; never marketed)
Peptide medicineIn Phase 2 testingDetailed recordUse listed on the medicine record
A growth hormone releaser designed to leave cortisol alone — never approved
Ligandrol (LGD-4033; developed as VK5211)
Small chemical medicineIn Phase 2 testingDetailed recordUse listed on the medicine record
Muscle loss after hip fracture — investigational only, and development stopped
Follistatin-344 (FS344; delivered in trials as AAV1.CMV.huFollistatin344. Sold online as "Follistatin 344" lyophilised powder)
Protein medicineIn Phase 2 testingDetailed recordUse listed on the medicine record
Blocks the brake on muscle growth — a gene therapy in trials, sold online as an injection
Zilebesiran (ALN-AGT01 (investigational))
RNA-silencing medicineIn Phase 2 testingDetailed recordUse listed on the medicine record
High blood pressure, dosed twice a year instead of daily
Ibutamoren (MK-677, also written MK-0677; ibutamoren mesylate)
Small chemical medicineIn Phase 2 testingDetailed recordUse listed on the medicine record
Age-related muscle loss and fracture recovery — investigational, and the programme ended
CJC-1295 (CJC-1295 with DAC. The product sold as "CJC-1295 without DAC" is a different molecule, modified GRF(1-29))
Peptide medicineIn Phase 2 testingDetailed recordUse listed on the medicine record
Raises growth hormone for a week per injection — no approved use anywhere